Specifically regulated genes in malignant melanoma tissues identified by subtractive hybridization

Autor Hipfel, R, Schittek, B, Bodingbauer, Y, Garbe, C
Vydáno 2000

Expression of interleukin 10 in human melanoma.

Autor Krüger-Krasagakes, S., Krasagakis, K., Garbe, C., Schmitt, E., Hüls, C., Blankenstein, T., Diamantstein, T.
Vydáno 1994

The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients.

Autor Häffner, A. C., Garbe, C., Burg, G., Büttner, P., Orfanos, C. E., Rassner, G.
Vydáno 1992

Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma

Autor Bauer, J, Kilic, E, Vaarwater, J, Bastian, B C, Garbe, C, de Klein, A
Vydáno 2009

Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors – Results of a Prospective Biomarker Study

Autor Forschner A, Weißgraeber S, Hadaschik D, Schulze M, Kopp M, Kelkenberg S, Sinnberg T, Garbe C, Biskup S, Battke F
Vydáno 2020-06-01

Determinants of survival in patients with brain metastases from cutaneous melanoma

Autor Staudt, M, Lasithiotakis, K, Leiter, U, Meier, F, Eigentler, T, Bamberg, M, Tatagiba, M, Brossart, P, Garbe, C
Vydáno 2010

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

Autor Radny, P, Caroli, U M, Bauer, J, Paul, T, Schlegel, C, Eigentler, T K, Weide, B, Schwarz, M, Garbe, C
Vydáno 2003

Naturally Processed Dermcidin-Derived Peptides Do Not Permeabilize Bacterial Membranes and Kill Microorganisms Irrespective of Their Charge

Autor Steffen, H., Rieg, S., Wiedemann, I., Kalbacher, H., Deeg, M., Sahl, H.-G., Peschel, A., Götz, F., Garbe, C., Schittek, B.
Vydáno 2006

Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis

Autor Weide, B, Elsässer, M, Büttner, P, Pflugfelder, A, Leiter, U, Eigentler, T K, Bauer, J, Witte, M, Meier, F, Garbe, C
Vydáno 2012

Microarchitecture Is Severely Compromised but Motor Protein Function Is Preserved in Dystrophic mdx Skeletal Muscle

Autor Friedrich, O., Both, M., Weber, C., Schürmann, S., Teichmann, M.D.H., von Wegner, F., Fink, R.H.A., Vogel, M., Chamberlain, J.S., Garbe, C.
Vydáno 2010

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

Autor Long, G V, Tykodi, S S, Schneider, J G, Garbe, C, Gravis, G, Rashford, M, Agrawal, S, Grigoryeva, E, Bello, A, Roy, A, Rollin, L, Zhao, X
Vydáno v Ann Oncol (2018)

Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

Autor Hauschild, A, Garbe, C, Stolz, W, Ellwanger, U, Seiter, S, Dummer, R, Ugurel, S, Sebastian, G, Nashan, D, Linse, R, Achtelik, W, Mohr, P, Kaufmann, R, Fey, M, Ulrich, J, Tilgen, W
Vydáno 2001

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

Autor Schadendorf, D., Amonkar, M. M., Milhem, M., Grotzinger, K., Demidov, L. V., Rutkowski, P., Garbe, C., Dummer, R., Hassel, J. C., Wolter, P., Mohr, P., Trefzer, U., Lefeuvre-Plesse, C., Rutten, A., Steven, N., Ullenhag, G., Sherman, L., Wu, F. S., Patel, K., Casey, M., Robert, C.
Vydáno v Ann Oncol (2014)

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

Autor Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J. B. A. G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M. A., Lane, S. R., Legos, J. J., Mookerjee, B., Grob, J.-J.
Vydáno v Ann Oncol (2017)

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

Autor Long, G V, Flaherty, K T, Stroyakovskiy, D, Gogas, H, Levchenko, E, de Braud, F, Larkin, J, Garbe, C, Jouary, T, Hauschild, A, Chiarion-Sileni, V, Lebbe, C, Mandalá, M, Millward, M, Arance, A, Bondarenko, I, Haanen, J B A G, Hansson, J, Utikal, J, Ferraresi, V, Mohr, P, Probachai, V, Schadendorf, D, Nathan, P, Robert, C, Ribas, A, Davies, M A, Lane, S R, Legos, J J, Mookerjee, B, Grob, J -J
Vydáno v Ann Oncol (2019)